KOHJIN BIO CO LTD (177A.T)
JPY 1703.0
(-0.12%)
JPY 1703.0
(-0.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 384 Million JPY | -53.61% |
| 2022 | 829.79 Million JPY | 41.2% |
| 2021 | 587.67 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | 384.97 Million JPY | -53.61% |
| 2023 Q4 | 177.84 Million JPY | 0.0% |
| 2022 FY | 829.79 Million JPY | 41.2% |
| 2021 FY | 587.67 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| PRISM BioLab Co.,LTD | -526.91 Million JPY | 172.877% |
| GNI Group Ltd. | 8.09 Billion JPY | 95.256% |
| Linical Co., Ltd. | 338.26 Million JPY | -13.52% |
| Trans Genic Inc. | 4.08 Million JPY | -9300.245% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | 126.705% |
| Soiken Holdings Inc. | -662.2 Million JPY | 157.988% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | -177.949% |
| AnGes, Inc. | -7.43 Billion JPY | 105.163% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 129.81% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 105.339% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | -105.684% |
| NanoCarrier Co., Ltd. | -780 Million JPY | 149.231% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | 133.307% |
| CanBas Co., Ltd. | -1.2 Billion JPY | 131.762% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | 147.267% |
| RaQualia Pharma Inc. | -323.66 Million JPY | 218.642% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | 131.475% |
| Kidswell Bio Corporation | -1.42 Billion JPY | 127.003% |
| PeptiDream Inc. | 3.03 Billion JPY | 87.351% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | 119.809% |
| Ribomic Inc. | -1.02 Billion JPY | 137.491% |
| SanBio Company Limited | -2.64 Billion JPY | 114.523% |
| Healios K.K. | -3.82 Billion JPY | 110.044% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 132.874% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | 125.779% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | 126.865% |
| StemRIM | -2.02 Billion JPY | 118.991% |
| CellSource Co., Ltd. | 923.14 Million JPY | 58.403% |
| FunPep Company Limited | -933.41 Million JPY | 141.139% |
| Kringle Pharma, Inc. | -854.15 Million JPY | 144.957% |
| Stella Pharma Corporation | -763.74 Million JPY | 150.278% |
| TMS Co., Ltd. | -960.04 Million JPY | 139.998% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | 133.982% |
| Cuorips Inc. | -632.18 Million JPY | 160.742% |
| K Pharma,Inc. | 260.33 Million JPY | -47.505% |
| Takara Bio Inc. | 1.48 Billion JPY | 74.054% |
| ReproCELL Incorporated | -31.41 Million JPY | 1322.346% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | -1355.759% |
| StemCell Institute Inc. | 310.98 Million JPY | -23.48% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | -168.214% |
| CellSeed Inc. | -846.53 Million JPY | 145.361% |